Key Insights

Highlights

Treatment Research

4 treatments under study, led by Ebvspecific Tcells

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Withdrawn1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT03988582Phase 2WithdrawnPrimary

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

NCT00917826Phase 2TerminatedPrimary

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Showing all 2 trials

Research Network

Common Treatments

  • Ebvspecific Tcells1
  • Valganciclovir1
  • Ganciclovir1
  • Arginine Butyrate1

Active Sponsors

  • Memorial Sloan Kettering Cancer Center1
  • HemaQuest Pharmaceuticals Inc.1
  • Boston University1

Top Investigators

Related Conditions

  • Ebvassociated Malignancies1
  • Lymphoproliferative Diseases1

Activity Timeline